Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP334329.RATVa5g8WbYB7hnGlSr4-n_sAx67DZEJIinLPDuuUpoio130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP334329.RATVa5g8WbYB7hnGlSr4-n_sAx67DZEJIinLPDuuUpoio130_assertion type Assertion NP334329.RATVa5g8WbYB7hnGlSr4-n_sAx67DZEJIinLPDuuUpoio130_head.
- NP334329.RATVa5g8WbYB7hnGlSr4-n_sAx67DZEJIinLPDuuUpoio130_assertion description "[These technologies have aided in the advancement of cancer vaccine development, as illustrated in examples including NY-ESO-1 originally defined by SEREX, and HER2/neu peptides analyzed via high-throughput epitope prediction methods.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP334329.RATVa5g8WbYB7hnGlSr4-n_sAx67DZEJIinLPDuuUpoio130_provenance.
- NP334329.RATVa5g8WbYB7hnGlSr4-n_sAx67DZEJIinLPDuuUpoio130_assertion evidence source_evidence_literature NP334329.RATVa5g8WbYB7hnGlSr4-n_sAx67DZEJIinLPDuuUpoio130_provenance.
- NP334329.RATVa5g8WbYB7hnGlSr4-n_sAx67DZEJIinLPDuuUpoio130_assertion SIO_000772 21732821 NP334329.RATVa5g8WbYB7hnGlSr4-n_sAx67DZEJIinLPDuuUpoio130_provenance.
- NP334329.RATVa5g8WbYB7hnGlSr4-n_sAx67DZEJIinLPDuuUpoio130_assertion wasDerivedFrom befree-20150227 NP334329.RATVa5g8WbYB7hnGlSr4-n_sAx67DZEJIinLPDuuUpoio130_provenance.
- NP334329.RATVa5g8WbYB7hnGlSr4-n_sAx67DZEJIinLPDuuUpoio130_assertion wasGeneratedBy ECO_0000203 NP334329.RATVa5g8WbYB7hnGlSr4-n_sAx67DZEJIinLPDuuUpoio130_provenance.